This is a highlights summary of an oral session given at the ADA 2021 - 81^st Scientific Sessions and presented by:

Jennifer B. Green, MD
Duke University Medical Center
Durham, NC, USA

The content is produced by Infomedica, the official reporting partner of ADA 2021. 

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Vivian Fonseca, MD 
Professor of Medicine and Pharmacology 
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes 
Chief, Section of Endocrinology
Tulane University Health Sciences Center 
New Orleans, USA

Vivian Fonseca, MD 
Professor of Medicine and Pharmacology 
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes 
Chief, Section of Endocrinology
Tulane University Health Sciences Center 
New Orleans, USA

Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, Assistant Dean for Clinical Research,  the Tullis-Tulane Alumni Chair in Diabetes, and Chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is a Past President for Science and Medicine of the American Diabetes Association (2012), and has served on the ADA Board of Directors and several committees. He has served on the Board of Directors of the American Association of Clinical Endocrinologists (AACE), and the Board of Trustees of the American College of Endocrinology. He has served on committees writing guidelines for both organizations. He has held a leadership role and served on various committees in several other organizations including the American Board of Internal Medicine. Dr. Fonseca has served on and been chairman of the clinical practice committee of the American Diabetes Association, the ADA Disaster Task Force, ADA strategic planning committee. He has played a significant role in developing guidelines for treating diabetes (ADA and AACE), managing chronic disease and clinical trials after a natural disaster, and in drawing attention to the global epidemic of diabetes, particularly in Asia. The American Diabetes Association awarded him the ADA Banting Medal for Leadership and Service and the Southern Medical Association awarded him the Seale-Harris award. The ADA presents the Vivian Fonseca Award annually for research on Diabetes in Asia. He has received several teaching awards and was elected to the Alpha Omega Alpha Honor Medical Society and has been listed for several years among the Best Doctors in the USA and for several years rated by Expertscape among the top 10 experts in Diabetes worldwide. Dr. Fonseca is a fellow of the Royal College of Physicians (London).

He plays a significant role in Clinical Research as Assistant Dean at Tulane University, and in its partnership with the Louisiana Clinical and Translational Science (LACaTS) Program. He is the Medical Director of the Tulane Clinical Trials Unit and Director of the Research Professional Development Core, which runs the Masters in Science in Clinical Research program.                 

He is Editor in Chief of the Journal of Diabetes and its Complications. He was Editor in chief of Diabetes Care, from 2007-2011, having formerly been associate editor. He was until 2006 Editor in Chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism, and is an ad hoc reviewer for several other journals, including New England Journal of Medicine, Lancet, JAMA, Diabetes, etc.

Dr. Fonseca’s research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease, particularly on the role of inflammation and other novel risk factors. He has a research program evaluating inflammation in diabetes, and using technology to improve diabetes care in underprivileged populations, especially the use of a new diabetes risk engine in clinical practice. He is the Louisiana PI of the All of Us Program, Southern Network and Co-PI of REACHnet, a large network that conducts research utilizing electronic health records of over 2 million people across several states.                              

Dr Fonseca has a strong interest in facilitating clinical research and developing the next generation of translational researchers.

Dr. Fonseca has lectured in the United States and abroad. He has published nearly 500 papers and review articles.  He is the editor of the text book “Clinical Diabetes: Translating Research into Practice” (Elsevier) and several monographs and book chapters.

 

 

Disclosures: Research Support (to Tulane): Grants from Fractyl, Jaguar Gene Therapy

 

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(suppl 1):S111–24.

2. Colling C, Atlas SJ, Wexler DJ, et al. Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Diabetes Care 2021;44:1–4.

3. Eberly LA, Yang L, Eneanya ND, et al. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Netw Open 2021;4(4):e216139.

4. Das SP, Everett BM, Birtcher KK, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol2020;76:1117.

5. Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. J Clin Endocrinol Metab 2019;104(8):3077–87.

6. American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(suppl 1):S211–20.

7. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2020;384(2):117–28.

8. Curtis LH, Mi X, Qualls LG, et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 2013;165(6):979–86.